3701-44-8 Usage
Uses
Used in Pharmaceutical Industry:
3-Ethoxyphenylisothiocyanate is used as a key intermediate in the synthesis of various pharmaceuticals. Its ability to introduce the isothiocyanate functional group makes it a valuable component in the development of new drugs and medicinal compounds.
Used in Dye Industry:
In the dye industry, 3-Ethoxyphenylisothiocyanate is utilized for the production of dyes. Its chemical properties allow for the creation of a range of colorants used in various applications, including textiles, plastics, and printing inks.
Used in Organic Synthesis:
3-Ethoxyphenylisothiocyanate is employed as a reagent in organic synthesis, particularly for the introduction of the isothiocyanate functional group. This group is essential for the formation of various organic compounds, contributing to the advancement of chemical research and development.
Used in Anticancer Research:
3-Ethoxyphenylisothiocyanate is studied for its potential as an anticancer agent. Its biological activities are of interest to researchers exploring new treatments for various types of cancer.
Used in Fungicide Development:
As a fungicide, 3-Ethoxyphenylisothiocyanate is being investigated for its potential to control fungal infections and diseases in agriculture and other industries. Its properties may contribute to the development of new and effective fungicidal products.
Check Digit Verification of cas no
The CAS Registry Mumber 3701-44-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,7,0 and 1 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 3701-44:
(6*3)+(5*7)+(4*0)+(3*1)+(2*4)+(1*4)=68
68 % 10 = 8
So 3701-44-8 is a valid CAS Registry Number.
3701-44-8Relevant articles and documents
Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders
Dolles, Dominik,Nimczick, Martin,Scheiner, Matthias,Ramler, Jacqueline,Stadtmüller, Patricia,Sawatzky, Edgar,Drakopoulos, Antonios,Sotriffer, Christoph,Wittmann, Hans-Joachim,Strasser, Andrea,Decker, Michael
supporting information, p. 1270 - 1283 (2016/07/27)
A pharmacophore model for butyrylcholinesterase (BChE) inhibitors was applied to a human cannabinoid subtype 2 receptor (hCB2R) agonist and verified it as a first-generation lead for respective dual-acting compounds. The design, synthesis, and pharmacological evaluation of various derivatives led to the identification of aminobenzimidazoles as second-generation leads with micro- or sub-micromolar activities at both targets and excellent selectivity over hCB1and AChE, respectively. Computational studies of the first- and second-generation lead structures by applying molecular dynamics (MD) on the active hCB2R model, along with docking and MD on hBChE, has enabled an explanation of their binding profiles at the protein levels and opened the way for further optimization. Dual-acting compounds with “balanced” affinities and excellent selectivities could be obtained that represent leads for treatment of both cognitive and pathophysiological impairment occurring in neurodegenerative disorders.